LDLeela R. L. Davies

Leela R. L. Davies

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leela R. L. Davies has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Age and sex influence antibody profiles associated with tuberculosis progression

    by Leela R. L. Davies, Chuangqi Wang, Pia Steigler, Kathryn A. Bowman, Stephanie Fischinger, Mark Hatherill, Michelle Fisher, Stanley Kimbung Mbandi, Miguel Rodo, Tom H. M. Ottenhoff, et al.

    Antibody features vary with tuberculosis (TB) disease state. Whether clinical variables, such as age or sex, influence associations between Mycobacterium tuberculosis-specific antibody responses and disease state is not well explored. Here we profiled Mycobacterium tuberculosis-specific antibody responses in 140 TB-exposed South African individuals from the Adolescent Cohort Study. We identified distinct response features in individuals progressing to active TB from non-progressing, matched controls. A multivariate antibody score differentially associated with progression (SeroScore) identified progressors up to 2 years before TB diagnosis, earlier than that achieved with the RISK6 transcriptional signature of progression. We validated these antibody response features in the Grand Challenges 6–74 cohort. Both the SeroScore and RISK6 correlated better with risk of TB progression in adolescents compared with adults, and in males compared with females. This suggests that age and sex are important, underappreciated modifiers of antibody responses associated with TB progression.


  • Open Access

    IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners

    by Leela R.L. Davies, Malisa T. Smith, Deniz Cizmeci, Stephanie Fischinger, Jessica Shih-Lu Lee, Lenette L. Lu, Erik D. Layton, Alison D. Grant, Katherine Fielding, Catherine M. Stein, et al.


  • Open Access

    Discrepancy between Mtb-specific IFN-γ and IgG responses in HIV-positive people with low CD4 counts

    by Maphe Mthembu, Kathryn A. Bowman, Leela R.L. Davies, Sharon Khuzwayo, Lusanda Mazibuko, Thierry Bassett, Dirhona Ramjit, Zoey Mhlane, Farina Karim, Galit Alter, et al.


  • Polysaccharide and conjugate vaccines to Streptococcus pneumoniae generate distinct humoral responses

    by Leela R. L. Davies, Deniz Cizmeci, Wenyue Guo, Corinne Luedemann, Ronika Alexander-Parrish, Lindsay Grant, Raul Isturiz, Christian Theilacker, Luis Jodar, Bradford D. Gessner, et al.

    Streptococcus pneumoniae is a major cause of community-acquired pneumonia, bacteremia, and meningitis in older adults worldwide. Two pneumococcal vaccines containing S. pneumoniae capsular polysaccharides are in current use: the polysaccharide vaccine PPSV23 and the glycoconjugate vaccine PCV13. In clinical trials, both vaccines elicit similar opsonophagocytic killing activity. In contrast to polysaccharide vaccines, conjugate vaccines have shown consistent efficacy against nasopharyngeal carriage and noninvasive pneumonia overall and for some prevalent individual serotypes. Given these different clinical profiles, it is crucial to understand the differential immunological responses induced by these two vaccines. Here, we used a high-throughput systems serology approach to profile the biophysical and functional features of serum antibodies induced by PCV13 and PPSV23 at 1 month and 1 year. In comparison with PPSV23, PCV13 induced higher titers across antibody isotypes; more durable antibody responses across immunoglobulin G (IgG), IgA, and IgM isotypes; and increased antigenic breadth. Although titers measured in opsonophagocytic activity (OPA) assays were similar between the two groups, confirming what was observed in clinical studies, serum samples from PCV13 vaccinees could induce additional non-OPA antibody-dependent functions, including monocyte phagocytosis and natural killer cell activation. In a multivariate modeling approach, distinct humoral profiles were demonstrated in each arm. Together, these results demonstrate that the glycoconjugate PCV13 vaccine induces an antigenically broader, more durable, polyfunctional antibody response. These findings may help explain the increased protection against S. pneumoniae colonization and noninvasive pneumonia and the longer duration of protection against invasive pneumococcal disease, mediated by PCV13.


  • Open Access

    Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis

    by Nadege Nziza, Deniz Cizmeci, Leela Davies, Edward B. Irvine, Wonyeong Jung, Brooke A. Fenderson, Marwou de Kock, Willem A. Hanekom, Kees L. M. C. Franken, Cheryl L. Day, et al.

    Tuberculosis (TB) is among the leading causes of death worldwide from a single infectious agent, second only to COVID-19 in 2020. TB is caused by infection with Mycobacterium tuberculosis (Mtb), that results either in a latent or active form of disease, the latter associated with Mtb spread. In the absence of an effective vaccine, epidemiologic modeling suggests that aggressive treatment of individuals with active TB (ATB) may curb spread. Yet, clinical discrimination between latent (LTB) and ATB remains a challenge. While antibodies are widely used to diagnose many infections, the utility of antibody-based tests to diagnose ATB has only regained significant traction recently. Specifically, recent interest in the humoral immune response to TB has pointed to potential differences in both targeted antigens and antibody features that can discriminate latent and active TB. Here we aimed to integrate these observations and broadly profile the humoral immune response across individuals with LTB or ATB, with and without HIV co-infection, to define the most discriminatory humoral properties and diagnose TB disease more easily. Using 209 Mtb antigens, striking differences in antigen-recognition were observed across latently and actively infected individuals that was modulated by HIV serostatus. However, ATB and LTB could be discriminated, irrespective of HIV-status, based on a combination of both antibody levels and Fc receptor-binding characteristics targeting both well characterized (like lipoarabinomannan, 38 kDa or antigen 85) but also novel Mtb antigens (including Rv1792, Rv1528, Rv2435C or Rv1508). These data reveal new Mtb-specific immunologic markers that can improve the classification of ATB versus LTB.